儿童复发霍奇金淋巴瘤的治疗及抗体靶向治疗进展
被引量：1
摘要
随着诊治水平的不断进展，国际上儿童霍奇金淋巴瘤（hodgkin lymphoma，HL）的治疗和管理已经进入了一个崭新时期，当代的治疗与以前传统的治疗方法比较已经明显改进，普遍采用了适于危险度、基于治疗反应分层治疗的策略以维持高疗效同时令其近、远期并发症最小化。在发达国家约95％的早期HL及80％以的上中、晚期HL患儿得以长期存活，目前已认为HL是一组恶性程度相对低、可治愈的肿瘤。
出处
《中国小儿血液与肿瘤杂志》
CAS
2014年第3期113-116,共4页
Journal of China Pediatric Blood and Cancer
基金
北京市医药管理局临床医学发展专项经费资助
编号:ZY201404
参考文献23
-
1Brenner H, Gondos A, Puhe D. Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Blood, 2008, 111:2977-2983.
-
2Daw S, Wynn R, Wallace H. Management of relapsed and refractory classical Hodgkin lymphoma in children and adolescents. Br J Haematol, 2011, 152:249-260.
-
3Harker-Murray PD, Drachtman RA, Hodgson DC, et al. Stratification of Treatment Intensity in Relapsed Pediatric Hodgkin Lymphoma. Pediatr Blood Cancer, 2014, 61:579-586.
-
4Schellong G, Dorffel W, Claviez A, et al. Salvage therapy of progressive and recurrent Hodgkin' s disease: results from a multicenter study of the Pediatric DAL/GPOH-HD Study Group. J Clin Oneol, 2005, 23: 618145189.
-
5Claviez A, Kabisch H, Suttorp M, et al. The impact of disease status at transplant and time to first relapse on outcome in children and adolescents with Hodgkin's lymphoma undergoing autologous stem cell transplantation. Blood ( ASH Annual Meeting Abstracts), 2004, 104: 1878.
-
6Lieskovsky YE, Donaldson SS, Torres MA, et al. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices. J Clin Oncol, 2004, 22: 4532-4540.
-
7Schwartz CL, Friedman DL, McCarten K, et al. Predictors of early response and event-free survival in Hodgkin lymphoma (HL) PET versus CT imaging. J Clin Oncol, 2011,29:8006.
-
8skowitz, CH, Nimer, SD, Zelenetz, AD, et al. A 2-step comprehensive high-dose chemo-radiotherapy second-lineprogram for relapsed and refractory Hodgkin disease: analysis byintent to treat and development of a prognostic model. Blood, 2001, 97:616-623.
-
9Josting A, Rudolph C, Mapara M, et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large muhicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol, 2005, 16: 116-123.
-
10Martin A, Fernandez-Jimenez MC, Caballero, MD, et al. Long-term follow up in patients treated with Mini-Beam as salvage therapy for relapsed or refractory Hodgkin's disease. Br J Haematol, 2001, 113: 161-171.
同被引文献42
-
1胡亚美,江载芳.诸福棠实用儿科学:下册[M].7版.北京:人民卫生出版社,2002:1809.
-
2Hunger SP, Raetz EA, Loh ML, et al. Improving outcomes for high-risk ALL: translating new discoveries into clinical care [J]. Pediatr Blood Cancer, 2011, 56 (6): 984-993.
-
3Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: A report from the Children's Oncology Group [J]. J Clin Oncol, 2012, 30 (14) :1663-1669.
-
4Goldman S, Smith L,Galardy P, et al. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/ leukaemia: a Children's Oncology Group Report [J]. Br J Haematol, 2014, 167 (3) : 394-401.
-
5Champagne MA, Fu CH, Chang M, et al. Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group [J]. Pediatr Blood Cancer, 2011, 57 (1) : 56-62.
-
6Schlegel P, Lang P, Zugmaier G, et al. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomabEJl. Haematologica, 2014, 99(7): 1212-1219.
-
7Ivanov A, Beers SA, Walshe CA, et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells [J]. J Clin Invest, 2009, 119 (8) : 2143-2159.
-
8Meinhardt A, Burkhardt B, Zimmermann M, et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia [J]. J Clin Oncol, 2010, 28 (19): 3115-3121.
-
9Boyiadzis M, Foon KA. Approved monoclonal antibodies for cancer therapy [Jl. Expert Opin Biol Ther, 2008, 8 (8) : 1151-1158.
-
10Herter S, Herring F, Mundigl O, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models [J]. Mol Cancer Ther, 2013, 12 (10): 2031-2042.
-
1王李君,娄世锋.血液系统肿瘤的抗体靶向治疗[J].中国肿瘤,2005,14(11):720-722.
-
2钟思思（编译）.有的放矢治疗乳腺癌[J].健康世界,2006(6):68-69.
-
3汤永民.儿童白血病抗体靶向治疗研究进展及临床应用前景[J].中国实用儿科杂志,2008,23(2):94-97.
-
4唐锋华.老年性急性肠梗阻的治疗体会[J].中国处方药,2014,12(1):104-105. 被引量：2
-
5姜文国,张树平,许勇,栾海云.4-1BBL基因转染Raji细胞增强利妥昔单抗活性的研究[J].临床肿瘤学杂志,2014,19(6):494-497. 被引量：1
-
6王霞光,吴秋格,寇怀刚.腱鞘囊肿4种治疗方法比较[J].实用乡村医生杂志,1997,4(3):26-26.
-
7张柏林,邢纪中,张俊义,周荣军.支气管动脉灌注化疗合并外照射治疗中晚期肺癌的疗效分析[J].中国肿瘤临床,2001,28(4):257-258. 被引量：2
-
8赵卫华.骨转移瘤疼痛的治疗方法比较(附60例分析)[J].广西医学,2000,22(3):599-600.
-
9张平,黄翼予,倪型灏.Ⅱ_A期宫颈腺癌治疗方法比较(附63例报告)[J].实用肿瘤杂志,1993,8(4):223-224. 被引量：3
-
10叶舜宾.恶性肿瘤的诊断问题[J].中国实验诊断学,2001,5(2):53-53.
